Search

Your search keyword '"Waters, David D."' showing total 227 results
Start Over Author "Waters, David D." Search Limiters Academic (Peer-Reviewed) Journals
227 results on '"Waters, David D."'

1. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Author

Tardif, Jean-Claude, Bouabdallaoui, Nadia, L'Allier, Philippe L, Gaudet, Daniel, Shah, Binita, Pillinger, Michael H, Lopez-Sendon, Jose, da Luz, Protasio, Verret, Lucie, Audet, Sylvia, Dupuis, Jocelyn, Denault, André, Pelletier, Martin, Tessier, Philippe A, Samson, Sarah, Fortin, Denis, Tardif, Jean-Daniel, Busseuil, David, Goulet, Elisabeth, Lacoste, Chantal, Dubois, Anick, Joshi, Avni Y, Waters, David D, Hsue, Priscilla, Lepor, Norman E, Lesage, Frédéric, Sainturet, Nicolas, Roy-Clavel, Eve, Bassevitch, Zohar, Orfanos, Andreas, Stamatescu, Gabriela, Grégoire, Jean C, Busque, Lambert, Lavallée, Christian, Hétu, Pierre-Olivier, Paquette, Jean-Sébastien, Deftereos, Spyridon G, Levesque, Sylvie, Cossette, Mariève, Nozza, Anna, Chabot-Blanchet, Malorie, Dubé, Marie-Pierre, Guertin, Marie-Claude, and Boivin, Guy

Published
2021
Full Text
View/download PDF

5. Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).

Author

Roubille, François, Bouabdallaoui, Nadia, Kouz, Simon, Waters, David D., Diaz, Rafael, Maggioni, Aldo P., Pinto, Fausto J., Grégoire, Jean C., Gamra, Habib, Kiwan, Ghassan S., Berry, Colin, López-Sendón, José, Koenig, Wolfgang, Delorme, Laurent, Elbaz, Meyer, Coste, Pierre, Provencher, Mylène, Bassevitch, Zohar, Blondeau, Lucie, and L’Allier, Philippe L.

Subjects
TYPE 2 diabetes, MYOCARDIAL infarction, COLCHICINE, CORONARY disease
Abstract

OBJECTIVE: The cardiovascular benefits of low-dose colchicine have been demonstrated in patients with coronary disease. Its effects were evaluated in this prespecified analysis in patients with type 2 diabetes (T2D) from the Colchicine Cardiovascular Outcomes Trial (COLCOT). RESEARCH DESIGN AND METHODS: COLCOT was a randomized, double-blinded trial of colchicine, 0.5 mg daily, versus placebo initiated within 30 days after a myocardial infarction. RESULTS: There were 959 patients with T2D enrolled and monitored for a median of 22.6 months. A primary end point event occurred in 8.7% of patients in the colchicine group and in 13.1% in the placebo group (hazard ratio 0.65; 95% CI 0.44–0.96; P = 0.03). Nausea was reported in 2.7% and 0.8% in the study groups (P = 0.03), and pneumonia occurred in 2.4% and 0.4% (P = 0.008). CONCLUSIONS: Among patients with T2D and a recent myocardial infarction, colchicine, 0.5 mg daily, leads to a large reduction of cardiovascular events. These results support the conduct of the COLCOT-T2D trial in primary prevention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk

Author

Arsenault, Benoit J., Petrides, Francine, Tabet, Fatiha, Bao, Weihang, Hovingh, G. Kees, Boekholdt, S. Matthijs, Ramin-Mangata, Stéphane, Meilhac, Olivier, DeMicco, David, Rye, Kerry-Anne, Waters, David D., Kastelein, John J.P., Barter, Philip, and Lambert, Gilles

Published
2018
Full Text
View/download PDF

15. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Author

Swerdlow, Daniel I, Preiss, David, Kuchenbaecker, Karoline B, Holmes, Michael V, Engmann, Jorgen E L, Shah, Tina, Sofat, Reecha, Stender, Stefan, Johnson, Paul C D, Scott, Robert A, Leusink, Maarten, Verweij, Niek, Sharp, Stephen J, Guo, Yiran, Giambartolomei, Claudia, Chung, Christina, Peasey, Anne, Amuzu, Antoinette, Li, KaWah, Palmen, Jutta, Howard, Philip, Cooper, Jackie A, Drenos, Fotios, Li, Yun R, Lowe, Gordon, Gallacher, John, Stewart, Marlene C W, Tzoulaki, Ioanna, Buxbaum, Sarah G, van der A, Daphne L, Forouhi, Nita G, Onland-Moret, N Charlotte, van der Schouw, Yvonne T, Schnabel, Renate B, Hubacek, Jaroslav A, Kubinova, Ruzena, Baceviciene, Migle, Tamosiunas, Abdonas, Pajak, Andrzej, Topor-Madry, Romanvan, Stepaniak, Urszula, Malyutina, Sofia, Baldassarre, Damiano, Sennblad, Bengt, Tremoli, Elena, de Faire, Ulf, Veglia, Fabrizio, Ford, Ian, Jukema, J Wouter, Westendorp, Rudi G J, de Borst, Gert Jan, de Jong, Pim A, Algra, Ale, Spiering, Wilko, der Zee, Anke H Maitland-van, Klungel, Olaf H, de Boer, Anthonius, Doevendans, Pieter A, Eaton, Charles B, Robinson, Jennifer G, Duggan, David, Kjekshus, John, Downs, John R, Gotto, Antonio M, Keech, Anthony C, Marchioli, Roberto, Tognoni, Gianni, Sever, Peter S, Poulter, Neil R, Waters, David D, Pedersen, Terje R, Amarenco, Pierre, Nakamura, Haruo, McMurray, John J V, Lewsey, James D, Chasman, Daniel I, Ridker, Paul M, Maggioni, Aldo P, Tavazzi, Luigi, Ray, Kausik K, Seshasai, Sreenivasa Rao Kondapally, Manson, JoAnn E, Price, Jackie F, Whincup, Peter H, Morris, Richard W, Lawlor, Debbie A, Smith, George Davey, Ben-Shlomo, Yoav, Schreiner, Pamela J, Fornage, Myriam, Siscovick, David S, Cushman, Mary, Kumari, Meena, Wareham, Nick J, Verschuren, W M Monique, Redline, Susan, Patel, Sanjay R, Whittaker, John C, Hamsten, Anders, Delaney, Joseph A, Dale, Caroline, Gaunt, Tom R, Wong, Andrew, Kuh, Diana, Hardy, Rebecca, Kathiresan, Sekar, Castillo, Berta A, van der Harst, Pim, Brunner, Eric J, Tybjaerg-Hansen, Anne, Marmot, Michael G, Krauss, Ronald M, Tsai, Michael, Coresh, Josef, Hoogeveen, Ronald C, Psaty, Bruce M, Lange, Leslie A, Hakonarson, Hakon, Dudbridge, Frank, Humphries, Steve E, Talmud, Philippa J, Kivimäki, Mika, Timpson, Nicholas J, Langenberg, Claudia, Asselbergs, Folkert W, Voevoda, Mikhail, Bobak, Martin, Pikhart, Hynek, Wilson, James G, Reiner, Alex P, Keating, Brendan J, Hingorani, Aroon D, and Sattar, Naveed

Published
2015
Full Text
View/download PDF

27. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.

Author

Tardif, Jean Claude, Pfeffer, Marc A, Kouz, Simon, Koenig, Wolfgang, Maggioni, Aldo P, McMurray, John J V, Mooser, Vincent, Waters, David D, Grégoire, Jean C, L'Allier, Philippe L, Jukema, J Wouter, White, Harvey D., Heinonen, Therese, Black, Donald M, Laghrissi-Thode, Fouzia, Levesque, Sylvie, Guertin, Marie Claude, Dubé, Marie Pierre, and Investigators, for the dal-GenE

Subjects
ACUTE coronary syndrome, ADENYLATE cyclase, MYOCARDIAL infarction, CARDIOVASCULAR disease related mortality, CARDIAC arrest
Abstract

Aims In a retrospective analysis of dal-Outcomes, the effect of dalcetrapib on cardiovascular events was influenced by an adenylate cyclase type 9 (ADCY9) gene polymorphism. The dal-GenE study was conducted to test this pharmacogenetic hypothesis. Methods and results dal-GenE was a double-blind trial in patients with an acute coronary syndrome within 1–3 months and the AA genotype at variant rs1967309 in the ADCY9 gene. A total of 6147 patients were randomly assigned to receive dalcetrapib 600 mg or placebo daily. The primary endpoint was the time from randomization to first occurrence of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke. After a median follow-up of 39.9 months, the primary endpoint occurred in 292 (9.5%) of 3071 patients in the dalcetrapib group and 327 (10.6%) of 3076 patients in the placebo group [hazard ratio 0.88; 95% confidence interval (CI) 0.75–1.03; P = 0.12]. The hazard ratios for the components of the primary endpoint were 0.79 (95% CI 0.65–0.96) for myocardial infarction, 0.92 (95% CI 0.64–1.33) for stroke, 1.21 (95% CI 0.91–1.60) for death from cardiovascular causes, and 2.33 (95% CI 0.60–9.02) for resuscitated cardiac arrest. In a pre-specified on-treatment sensitivity analysis, the primary endpoint event rate was 7.8% (236/3015) in the dalcetrapib group and 9.3% (282/3031) in the placebo group (hazard ratio 0.83; 95% CI 0.70–0.98). Conclusion Dalcetrapib did not significantly reduce the risk of occurrence of the primary endpoint of ischaemic cardiovascular events at end of study. A new trial would be needed to test the pharmacogenetic hypothesis that dalcetrapib improves the prognosis of patients with the AA genotype. Clinical Trial Registration Trial registration dal-GenE ClinicalTrials.gov Identifier: NCT02525939 [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

Author

Preiss, David, Campbell, Ross T., Murray, Heather M., Ford, Ian, Packard, Chris J., Sattar, Naveed, Rahimi, Kazem, Colhoun, Helen M., Waters, David D., LaRosa, John C., Amarenco, Pierre, Pedersen, Terje R., Tikkanen, Matti J., Koren, Michael J., Poulter, Neil R., Sever, Peter S., Ridker, Paul M., MacFadyen, Jean G., Solomon, Scott D., Davis, Barry R., Simpson, Lara M., Nakamura, Haruo, Mizuno, Kyoichi, Marfisi, Rosa M., Marchioli, Roberto, Tognoni, Gianni, Athyros, Vasilios G., Ray, Kausik K., Gotto, Antonio M., Clearfield, Michael B., Downs, John R., and McMurray, John J.

Published
2015
Full Text
View/download PDF

34. Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

Author

Faergeman, Ole, Holme, Ingar, Fayyad, Rana, Bhatia, Sonal, Grundy, Scott M., Kastelein, John J.P., LaRosa, John C., Larsen, Mogens Lytken, Lindahl, Christina, Olsson, Anders G., Tikkanen, Matti J., Waters, David D., and Pedersen, Terje R.

Published
2009
Full Text
View/download PDF

35. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial†

Author

Tardif, Jean-Claude, Ballantyne, Christie M., Barter, Philip, Dasseux, Jean-Louis, Fayad, Zahi A., Guertin, Marie-Claude, Kastelein, John J. P., Keyserling, Constance, Klepp, Heather, Koenig, Wolfgang, LʼAllier, Philippe L., Lespérance, Jacques, Lüscher, Thomas F., Paolini, John F., Tawakol, Ahmed, Waters, David D., Pfeffer, M., Brown, V., Rouleau, J., Watkins, P., Wei, L.J., Gosselin, G., Chayer, C., Lanthier, S., Pelletier, G.B., Racine, N., Agarwal, H., Brilakis, E., Cannon, L., Carrié, D., Corbelli, J., Coste, P., de Winter, R., Diaz, A., Eisenberg, S., Ennis, B., Fajadet, J., Fam, N., Fortuin, D., Gessler, C., Grines, C., Guerra, D., Gum, H., Haldis, T., Heestermans, T., Herrman, J.P., Huynh, T., Kedhi, E., Koren, M., Kouz, S., Krolick, M., Kumkumian, G., Lavi, S., Li, R.J., Masud, ARZ, McAlhany, C., McGrew, F.A., OʼShaughnessy, C., Oude Ophuis, A.J.M., Parr, K., Penny, W., Pesant, Y., Post, H., Robinson, S., Rodes-Cabau, J., Roy, A., Schulman, S., Spence, F., Stouffer, G., Stys, T., Sussex, B., Tahirkheli, N., Tardif, J-C., Grégoire, J., ten Berg, J., van Boven, A.J., von Birgelen, C., and Weinstein, D.

Published
2014
Full Text
View/download PDF

41. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A.sub.2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

Author

Rosenson, Robert S., Hislop, Colin, McConnell, Daniel, Elliott, Michael, Stasiv, Yuri, Wang, Nan, and Waters, David D.

Subjects
Phospholipases -- Physiological aspects, Atherosclerosis -- Risk factors, Atherosclerosis -- Development and progression, Blood lipoproteins -- Physiological aspects, Lipoproteins -- Physiological aspects, Proteolipids -- Physiological aspects, Coronary heart disease -- Physiological aspects
Published
2009

42. Effects of torcetrapid in patients at high risk for coronary events

Author

Barter, Philip J., Caulfield, Mark, Eriksson, Mats, Grundy, Scott M., Kastelein, John J.P., Komajda, Michel, Lopez-Sendon, Jose, Mosca, Lori, Tardif, Jean-Claude, Waters, David D., Shear, Charles L., Revkin, James H., Buhr, Kevin A., Risher, Marian R., Tall, Alan R., and Brewer, Bryan

Subjects
Torcetrapib (Medication) -- Research, Torcetrapib (Medication) -- Complications and side effects, Anticholesteremic agents -- Research, Anticholesteremic agents -- Complications and side effects, Heart -- Abnormalities, Heart -- Risk factors
Abstract

A randomized, double-blind trial was conducted to determine efficacy of torcetrapib, a potent cholesteryl ester transfer protein inhibitor to reduce major cardiovascular events. The trial was terminated prematurely as it increased risk of death and cardiac events in patients receiving torcetrapib.

Published
2007

43. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study

Author

Deedwania, Prakash, Barter, Philip, Carmena, Rafael, Fruchart, Jean-Charles, Grundy, Scott M, Haffner, Steven, Kastelein, John JP, LaRosa, John C, Schachner, Holly, Shepherd, James, and Waters, David D

Subjects
Coronary heart disease -- Care and treatment, Low density lipoproteins -- Health aspects, Low density lipoproteins -- Control, Metabolic syndrome X -- Care and treatment
Published
2006

44. Intensive lipid lowering with atorvastatin in patients with stable coronary disease

Author

LaRosa, John C., Fruchart, Jean-Charles, Wenger, Nanette K., Gotto, Antonio M., Grundy, Scott M., Waters, David D., Greten, Heiner, Shear, Charles, Kastelein, John J.P., Barter, Philip, and Shepherd, James

Subjects
Coronary heart disease -- Care and treatment, Cholesterol, LDL -- Measurement
Abstract

Lowering low-density lipoprotein (LDL) cholesterol levels below recommended levels is beneficial in patients with acute coronary syndromes. Intensive lipid-lowering therapy with 80mg of atorvastatin per day in patients with stable coronary heart disease (CHD) provides significant clinical benefit beyond that afforded by treatment with 10mg of atorvastatin per day.

Published
2005

47. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.

Author

Waters, David D., Alderman, Edwin L., Hsia, Judith, Howard, Barbara V., Cobb, Frederick R., Rogers, William J., Ouyang, Pamela, Thompson, Paul, Tardif, Jean Claude, Higginson, Lyall, Bittner, Vera, Steffes, Michael, Gordon, David J., Proschan, Michael, Younes, Naji, and Verter, Joel I.

Subjects
Antioxidants -- Health aspects, Vitamins -- Health aspects, Coronary heart disease -- Development and progression, Hormone therapy -- Evaluation
Abstract

Neither hormone replacement therapy (HRT) nor antioxidant vitamins can slow the progression of coronary artery disease, according to a study of 423 postmenopausal women with coronary artery disease. In fact, HRT and vitamins appeared to make the disease progress faster. This was documented by angiography, a technique that can measure the inside of the coronary arteries.

Published
2002

50. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis

Author

Preiss, David, Seshasai, Sreenivasa Rao, Welsh, Paul, Murphy, Sabina A., Ho, Jennifer E., Waters, David D., DeMicco, David A., Barter, Philip, Cannon, Christopher P., Sabatine, Marc S., Braunwald, Eugene, Kastelein, John J., de Lemos, James A., Blazing, Michael A., Pedersen, Terje R., Tikkanen, Matti J., Sattar, Naveed, and Ray, Kausik K.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results